Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Kicks Off New Year With Exelixis Deal For MEK Inhibitor

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech joins Pfizer and AstraZeneca in developing the new class of oncology compounds.

You may also be interested in...



Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets

Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.

Celgene Collaborates With Array BioPharma On Cancer, Inflammation Targets

Deal does not include candidates already in Array’s pipeline, firm tells “The Pink Sheet” DAILY.

AstraZeneca Set For Boston Area Growth Spurt

$100 million expansion will add 132,000 square feet of lab space for research in infectious disease and cancer by 2009.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel